1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Ms E Walmsley
|
|
b)
|
Position/status
|
Chief
Executive Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary
Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 July 2019, on shares held
through the Company's Share Reward Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.5060
|
19
|
||
d)
|
Aggregated
information
Aggregated volume
Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-07-11
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr R G Connor
|
|
b)
|
Position/status
|
President, Global Vaccines
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary
Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 July 2019, on shares held
through the Company's Share Reward Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.5060
|
62
|
||
d)
|
Aggregated
information
Aggregated volume
Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-07-11
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr N Hirons
|
|
b)
|
Position/status
|
SVP, Global Ethics & Compliance
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 July 2019, on shares held
through the Company's Share Reward Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.5060
|
12
|
||
d)
|
Aggregated
information
Aggregated
volume
Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-07-11
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mrs S Jackson
|
|
b)
|
Position/status
|
SVP, Global Communications and CEO Office
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 July 2019, on shares held
through the Company's Share Reward Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.5060
|
57
|
||
d)
|
Aggregated
information
Aggregated
volume
Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-07-11
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr D Jackson
|
|
b)
|
Position/status
|
PCA of Mrs S Jackson (SVP, Global Communications and CEO
Office)
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 July 2019, on shares held
through the Company's Share Reward Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.5060
|
19
|
||
d)
|
Aggregated
information
Aggregated
volume
Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-07-11
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr L Miels
|
|
b)
|
Position/status
|
President,
Global Pharmaceuticals
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary
Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 July 2019, on shares held
through the Company's Share Reward Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.5060
|
3
|
||
d)
|
Aggregated
information
Aggregated volume
Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-07-11
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr D S Redfern
|
|
b)
|
Position/status
|
Chief Strategy Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 July 2019, on shares held
through the Company's Share Reward Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.5060
|
70
|
||
d)
|
Aggregated
information
Aggregated volume
Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-07-11
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr R Simard
|
|
b)
|
Position/status
|
President, Pharmaceuticals Supply Chain
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 July 2019, on shares held
through the Company's Share Reward Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.5060
|
19
|
||
d)
|
Aggregated
information
Aggregated
volume
Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-07-11
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr P C Thomson
|
|
b)
|
Position/status
|
President,
Global Affairs
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary
Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 July 2019, on shares held
through the Company's Share Reward Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.5060
|
40
|
||
d)
|
Aggregated
information
Aggregated volume
Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-07-11
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mrs V A Whyte
|
|
b)
|
Position/status
|
Company Secretary
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 July 2019, on shares held
through the Company's Share Reward Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.5060
|
51
|
||
d)
|
Aggregated
information
Aggregated volume
Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-07-11
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: July
12, 2019
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|